Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505271 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study Using Rexin-G for Breast Cancer
A Phase 1 study, sponsored by Epeius Biotechnologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00505271 is a Phase 1 study that has completed, run by Epeius Biotechnologies. The registered enrollment target is 20 participants.
The verdict
NCT00505271, a Phase 1 study, has completed, sponsored by Epeius Biotechnologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol for recurrent or metastatic breast cancer.
Interventions
- GENETIC Rexin-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505271
The ClinicalTrials.gov registry entry for NCT00505271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epeius Biotechnologies, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rexin-G is the first listed.
NCT00505271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505271 about?
NCT00505271 is a clinical study titled "Safety and Efficacy Study Using Rexin-G for Breast Cancer". The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol for recurrent or metastatic breast cancer.
What is the current status of trial NCT00505271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-07. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00505271?
The interventions under investigation include: Rexin-G (GENETIC).
Who is sponsoring clinical trial NCT00505271?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.